Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination
Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine
Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
TBE Seropersistence up to 10 Years After First Booster in Adults
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory
Postencephalitic Symptoms After Tick Borne Encephalitis
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
Influence of Persistent CMV-infection on Immune Senescence
Aseptic Meningoencephalitis in Slovenia
† Study has passed its completion date and status has not been verified in more than two years.